Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

VERNALIS PLC (VER)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Vernalis plc
Researches and develops pharmaceutical products

Vernalis Plc is a commercial stage pharmaceutical company.

Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market; Moxatag, a once-a-day formulation of the antibiotic and amoxicillin; and frovatriptan, used for the acute treatment of migraine.

Vernalis also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market.

The company was founded by Keith G. McCullagh in 1986 and is headquartered in Winnersh, United Kingdom.

Number of employees : 115 persons.
Sales per Businesses
20162017Delta
GBP (in Million)%GBP (in Million)%
Research & Development8.0466.8%14.4069.3% +79.12%
Commercial3.9933.2%6.3930.7% +59.96%
Sales per Regions
20162017Delta
GBP (in Million)%GBP (in Million)%
Rest of Europe8.1367.6%14.2468.5% +75.05%
Rest of the World2.7322.7%1.989.5% -27.72%
North America1.169.7%4.5822% +293.89%
United Kingdom0.0050%---
Managers
NameAgeSinceTitle
Ian Garland522008Chief Executive Officer & Executive Director
Sandford Sommer-2016President & Chief Operating Officer
Peter John Fellner, PhD732003Non-Executive Chairman
David MacKney492009Chief Financial Officer & Executive Director
Mike Wood-2004Research Director
Pascal Borderies, MD-2014Senior Vice President-Medical Affairs
Carol C. Ferguson702003Senior Independent Non-Executive Director
Nigel Sheail522011Independent Non-Executive Director
Ian David Gilham, PhD572015Independent Non-Executive Director
Lisa Amster Schoenberg, MBA512015Independent Non-Executive Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 526,472,145 519,921,208 98.8% 0 0.0% 98.8%
Shareholders
NameEquities%
Invesco Asset Management Ltd. 194,417,167 36.9%
Woodford Investment Management Ltd. 157,876,138 30.0%
GAM London Ltd. 47,808,756 9.08%
Legal & General Investment Management Ltd. 28,844,930 5.48%
Aviva Investors Global Services Ltd. 23,921,703 4.54%
Medical Strategy GmbH 5,898,929 1.12%
TD Direct Investing (Europe) Ltd. 5,051,000 0.96%
Hargreaves Lansdown Asset Management Ltd. 4,214,000 0.80%
River & Mercantile Asset Management LLP 2,996,000 0.57%
Hargreaves Lansdown Stockbrokers Ltd. 2,388,000 0.45%
Company contact information
Vernalis Plc
100 Berkshire Place
Wharfedale Road
Winnersh, Berkshire RG41 5RD

Phone : +44.118.938.0000
Fax : +44.118.938.0001
Web : www.vernalis.com
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
VERNALIS PLC-65.44%83
CELLTRION, INC.--.--%23 085
IQVIA HOLDINGS INC32.70%21 148
INCYTE CORPORATION-5.43%20 523
LONZA GROUP57.44%19 299
ALNYLAM PHARMACEUTICALS, INC.243.83%12 606
NEKTAR THERAPEUTICS346.86%8 694
ALKERMES PLC-5.04%8 021
SEATTLE GENETICS, INC.8.53%7 954
QIAGEN NV7.36%7 216
SAGE THERAPEUTICS INC206.05%6 705
IONIS PHARMACEUTICALS INC12.75%6 608
EXACT SCIENCES CORPORATION307.49%6 221
ICON PLC47.79%6 008
UNITED THERAPEUTICS CORPORATION-4.43%5 860
PRA HEALTH SCIENCES INC48.04%5 307
CHARLES RIVER LABORATORIES INTL. INC35.36%4 921
BIO-TECHNE CORP25.35%4 758
GALAPAGOS20.51%4 561
INC RESEARCH HOLDINGS INC-24.81%4 283
PUMA BIOTECHNOLOGY INC242.02%3 796
© 2017 People , Fundamentals and Ownership